Monitoring gene expression and transcriptome changes with cancer RNA sequencing (RNA-Seq) can aid in understanding tumor classification and progression. Cancers accumulate numerous genetic changes, but typically only a few drive tumor progression. Cancer RNA-Seq can help to determine which variants are expressed in cancer samples.
Clinical researchers at Avera Health rely on next-generation sequencing to uncover multiple drug-susceptible tumorigenic pathways.
Read Interview
Researchers are using RNA-Seq to reveal how lncRNAs could be used to identify, measure, and treat cancer.
Read Interview
Researchers compared two TruSeq RNA kits to identify the optimal library prep method for their cancer gene expression studies.
Read InterviewSequencing the coding regions or the whole cancer transcriptome can provide valuable information about gene expression changes in tumors. Cancer RNA-Seq enables detection of strand-specific information, an important component of gene regulation. Cancer transcriptome sequencing captures both coding and noncoding RNA and provides strand orientation for a complete view of expression dynamics.
Learn More About RNA-SeqTargeted RNA amplicon sequencing analyzes the expression of specific cancer genes. Predesigned cancer gene expression panels focus on relevant pathways, such as p53 and NFκB. Researchers can add custom content to broaden the scope of an experiment.
Learn About Targeted Amplicon RNA-SeqRNA sequencing (RNA-Seq) is increasingly being used to discover and profile RNA-based drug response biomarkers. Find resources designed to help you adopt RNA-Seq for biomarker analysis, including a workflow introduction, experimental considerations, and start-up advice.
Learn More
Genomic regions containing deleted or amplified miRNA loci have been linked to multiple forms of cancer. Small RNA-Seq enables the discovery and profiling of miRNAs and other small, noncoding RNAs present in the cancer transcriptome.
Learn More About Small RNA-SeqFormalin-fixed, paraffin-embedded (FFPE) tumor samples potentially contain valuable information about cancer pathogenesis and outcomes. Because FFPE samples generally contain partially degraded RNA, cancer RNA-Seq can pose challenges. Next-generation RNA-Seq methods enable researchers to access this important data, yielding high-quality results from degraded and FFPE-derived RNA.
Learn About FFPE RNA-SeqIllumina offers several library preparation, sequencing, and data analysis options for cancer RNA sequencing. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. Illumina systems deliver industry-leading data quality—in fact, approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.
Push-button apps in BaseSpace Sequence Hub simplify data analysis, so you can spend less time analyzing data and more time focusing on the next breakthrough.
Click on the below to view products for each workflow step.
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.
TruSight Tumor 170Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.
TruSeq RNA ExomeA reproducible, economical method for sequencing coding RNA from FFPE and other low-quality samples.
TruSeq Targeted RNA Expression KitPredesigned or custom panels for cancer gene expression profiling.
Precise measurement of mRNA strand orientation for detection of antisense transcription and discovery of alternative transcripts, gene fusions, and allele-specific expression.
TruSeq Stranded Total RNA Library Prep KitScalable solution for whole-transcriptome analysis that delivers accurate strand information for a complete view of the transcriptome.
TruSeq Small RNA Library Prep KitSensitive kit for microRNA analysis.
Simplest and most affordable solution for low-throughput targeted gene expression profiling.
MiSeq SystemDesktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.
MiSeqDx InstrumentFDA-cleared in vitro diagnostic NGS system that also operates in research mode to generate accurate, reliable data.
Flexible desktop sequencing system to perform various cancer RNA-Seq applications, including whole-transcriptome analysis and cancer gene expression profiling.
HiSeq 4000 SystemUltra-high-throughput systems for production-scale cancer RNA-Seq experiments.
NovaSeq 6000 SystemScalable throughput and flexibility for virtually any genome, sequencing method, and scale of project.
Aligns RNA reads with the STAR aligner, followed by differential expression with DESeq2.
TopHat Alignment AppPerforms spliced alignment, variant calling, and reference quantification for RNA samples.
Cufflinks Assembly & DE AppPerforms novel transcript assembly and differential expression analysis on RNA samples.
Easy-to-use software for analysis and variant calling on the MiSeq System.
BaseSpace Sequence HubThe Illumina genomics computing environment for NGS data analysis and management.
BaseSpace Correlation EngineA growing library of curated genomic data to support researchers in identifying disease mechanisms, drug targets, and prognostic or predictive biomarkers.
Learn about RNA-Seq for cancer transcriptome analysis of single cells.
Learn how cancer RNA-Seq can provide detailed information about gene expression in tumors.
A new enrichment-based cancer research assay interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants.
An overview of recent cancer research publications featuring Illumina technology.
Molecular profiling that combines DNA- and RNA-level data can more easily identify genes that may be driving cancer.